INTRODUCTION
Osteoarthritis (OA) is a major public health problem and a leading cause of disability.
The knee joint is commonly affected and it is estimated that 10% of people aged over 60 years experience knee OA symptoms, 1 resulting in substantial pain and physical dysfunction. 2 3 Current evidence demonstrates beneficial effects of exercise therapy on pain and physical function in knee OA, without the common and sometimes serious side effects associated with pharmacological and surgical interventions. 4 Consequentially, exercise is considered the cornerstone of conservative management and is recommended in all clinical guidelines internationally. 5 6 Although exercise is effective in knee OA, meta-analyses indicate its treatment benefits are moderate for pain (standardised mean difference (SMD) −0.49, 95% CI −0.39 to −0.59) and physical function (SMD −0.52, 95% CI −0.39 to −0.64), 7 and are similar to those achieved with pharmacological treatments. 8 Novel treatments that bolster the effect of exercise therapy have the potential to further improve outcomes in knee OA.
OA is a joint disorder that affects the cartilage and bone. Although pain is often attributed to localised joint pathology, research has shown that pain intensity does not always
Strengths and limitations of this study
▪ A randomised, assessor-blind and participantblind, sham-controlled trial. ▪ Our study is the first to provide information on the feasibility and safety of a combined brain stimulation and exercise intervention in knee osteoarthritis. ▪ If trends of effectiveness are present, may provide data for a fully powered trial. ▪ This is a feasibility study and as such, is not powered to determine treatment effectiveness. ▪ The treating physiotherapist is not blinded to group allocation.
correlate with the severity of joint structural damage or the presence of inflammation. 9 10 This discrepancy may be explained by the presence of a central component to persistent pain in knee OA. For example, nociceptive input from structural joint changes in OA may enhance the excitability and efficiency of synapses in the central pain pathway, a phenomenon termed central sensitisation. 11 In support of this hypothesis, a recent systematic review demonstrated that central sensitisation contributes to persistent OA pain, characterised by local and widespread hyperalgesia (such as reduced pressure and thermal pain thresholds), increased spinal excitability (increased nociceptive flexion withdraw reflex), and deficits in descending pain processing (altered conditioned pain modulation). 12 Treatments that target central sensitisation and pain processing may, therefore, be effective in knee OA.
The safe and painless application of weak direct electrical currents over the scalp (transcranial direct current stimulation, tDCS) is a novel intervention that has the potential to reduce central sensitisation and improve pain processing in knee OA. Using surface electrodes, direct current applied to the brain can increase (anodal stimulation) or decrease (cathodal stimulation) excitability of the region below the electrode as well as distant interconnected areas. [13] [14] [15] Studies of healthy individuals and patients with persistent pain suggest anodal tDCS applied to the primary motor cortex can reduce pain, a finding thought to be explained by direct effects of stimulation on the cortex and thalamus, [16] [17] [18] [19] [20] [21] as well as 'downstream' effects on the anterior cingulate cortex and upper brain stem. 22 23 However, there has been no research investigating the effect of tDCS, whether applied alone or in combination with other interventions, in people with osteoarthritic pain. Exercise, moreover, can exert central as well as peripheral effects. Exercise treatments can alter sensory input from the periphery by modification of muscle control (ie, muscle coordination and strength) and through improved proprioception to enhance control of the affected joint, thus reducing nociceptor discharge and enhancing normal sensory input. Centrally, exercise is known to have an analgesic effect that reduces pain sensitivity in healthy individuals. 24 25 This is thought to be due to activation of opioidergic mechanisms and enhanced descending pain control systems. 26 27 Treatments that modify peripheral inputs (exercise), and treatments that modify processing of these inputs at the supraspinal level (tDCS and exercise) may summate to produce greater effects on pain and function. In addition, tDCS has the potential to increase the brain's receptiveness to other interventions by increasing cortical excitability, a phenomenon known as priming. 28 Thus, tDCS may optimise the responsiveness of the brain to exercise and improve outcomes beyond that which can be achieved with tDCS or exercise alone. Despite this, no study has examined the effect of a combined tDCS and exercise intervention in any persistent pain condition.
Therefore, the aims of this pilot randomised controlled trial are to (1) determine the feasibility, safety and perceived patient response to a combined tDCS and exercise intervention in knee OA and (2) provide data to support a sample size calculation for a fully-powered trial should trends of effectiveness be present.
METHODS AND ANALYSIS Trial design
We will conduct a pilot randomised, assessor-blind and participant-blind, controlled trial. The trial will be reported according to the Consolidated Standards of Reporting Trials (CONSORT) statement for non-pharmacological treatment, 29 and the template for intervention description and replication (TIDieR) checklist and guide. 30 It has been prospectively registered with the Australian and New Zealand Clinical Trials Registry (365331).
Participants
Participants with knee OA that meet the American College of Rheumatology clinical classification for idiopathic knee OA criteria 31 will be recruited from the community. The criteria include the presence of knee pain plus at least three of the following six items: age over 50 years, morning stiffness lasting less than 30 min, crepitus, bony tenderness, bony enlargement and no palpable warmth. A minimum pain score of 40 on a 100 mm visual analogue scale (VAS) on walking in the last week will be required. The main exclusion criteria are: (1) knee surgery in the past 6 months; (2) knee joint replacement or high tibial osteotomy on the affected side; (3) other muscular, joint or neurological conditions affecting lower limb function; (4) unable to walk unaided; (5) currently undertaking a structured exercise programme for knee OA or (6) contraindications to tDCS (eg, epilepsy) or conditioned pain modulation techniques (eg, loss of sensation). Participants can continue to use their normal medication for the duration of the trial. The type of medication and dosage used will be recorded at the baseline assessment.
Recruitment
Participants will be recruited from local arthritis support groups, social media and healthcare providers (medical practitioners, rheumatologists and physiotherapists). Potential participants will first complete an online screening questionnaire to determine their eligibility. Those who meet the inclusion criteria will be contacted by one of the investigators to confirm their willingness to participate in the trial and to arrange the baseline assessment of outcomes. Participants will provide written informed consent on arrival for baseline assessment.
Randomisation
Participants will be individually randomised on a 1:1 basis to the active or control groups in equal numbers. The randomisation schedule will be concealed in consecutively numbered, sealed opaque envelopes. An investigator not involved in recruitment or assessment will provide the envelope to the treating clinician who will reveal group allocation.
Blinding
Participants and the outcome assessor will be blinded to group allocation. The treating physiotherapist will deliver the tDCS intervention and the exercise therapy and will, therefore, not be blinded to group allocation. The success of participant blinding will be assessed at the follow-up assessment using a 'yes/no' response to the question "Do you feel you received the real brain stimulation?" and a 10 cm VAS of the individual's confidence in that judgement. Participants will also be asked "Why do you believe you received the real/sham brain stimulation?" and "Was it divulged to you whether you were receiving real brain stimulation or not?". The success of assessor blinding will be determined at the completion of the follow-up assessment for each participant using a 'yes/no' response to the question "Did you know which intervention group the participant was assigned to before completion of the follow-up assessment?" and "If you answer 'yes', how was it divulged to you?".
Intervention
Participants will be randomly allocated to one of two treatment groups: (1) active tDCS plus exercise or (2) sham tDCS plus exercise. All participants will receive 20 min of either active or sham tDCS immediately prior to 30 min of supervised muscle strengthening exercise, two times per week for 8 weeks. A qualified physiotherapist who is trained in the use of tDCS will deliver the tDCS interventions and the exercise therapy in a consulting room of the UniClinic at the University of Western Sydney. The physiotherapist has a Bachelor of Science in Physiotherapy and 6 years of clinical experience. Participants in both groups will also be instructed to complete home exercises twice per week to mimic typical clinical practice. Outcome measures will be assessed immediately before and immediately after the 8-week intervention.
Transcranial direct current stimulation Participants will be comfortably seated in an armchair while receiving tDCS and will be asked to remain quiet for the duration of the intervention. tDCS will be delivered for 20 min using a direct current stimulator (DC-STIMULATOR, neuroConn, Ilmenau, Germany) via two 35 cm 2 surface sponge electrodes. The active electrode (anode) will be placed over the primary motor cortex contralateral to the side of worst pain and the reference electrode (cathode) over the contralateral supraorbital region. 21 Current intensity will be ramped up (0-1 mA) and down (1-0 mA) over 10 s at the beginning and end of the stimulation period. For sham stimulation, electrodes will be placed in an identical position.
Stimulation will be turned on for 15 s and then off, to provide the initial itching sensation. Participants will be informed that they may or may not perceive any sensation during the treatment. This procedure has been shown to effectively blind participants to the stimulation condition. 32 
Exercise
Immediately following the tDCS intervention, participants will start one-to-one exercise therapy supervised by the physiotherapist. A standardised set of quadriceps strengthening exercises that are known to be effective in knee OA (table 1) will be performed with ankle cuff weights or resistance bands where necessary. 7 33 Exercise intensity will be progressed by the physiotherapist as appropriate for each participant. Each exercise session will last 30 min. A home exercise plan will be developed, monitored and progressed by the physiotherapist for each participant. An exercise diary with written and visual instructions for each exercise (including dosage) will be provided to each participant. The exercise diary will include space for participants to outline which exercises were completed, how many repetitions were performed and any comments regarding the home exercise programme (eg, whether pain was present, whether any exercises were difficult and if applicable, the reason why exercises were unable to be completed). The exercise diary will be returned to the investigator at the follow-up assessment session.
As the aim of this trial is to use tDCS to boost the effect of exercise, the intervention duration has been selected based on the number of sessions required to achieve efficacious outcomes using exercise alone in knee OA. An 8-week exercise duration period has been chosen based on evidence that at least 12 sessions of supervised exercise are required for exercise to be effective in knee OA, 7 with a number of studies demonstrating symptom improvement in knee OA after 8-12 weeks of exercise. 34 Thus, 8 weeks (16 sessions) should be sufficient to show improvement in this population.
Outcome measurements
Baseline and follow-up assessments will be performed within 1 week of the participant starting or completing the intervention, respectively. All outcome measures will be performed in the research laboratories of the University of Western Sydney.
Measures of pain and function
Knee pain and function will be measured using (1) a 100 mm VAS with pain on walking over the last week selfassessed with terminal descriptors of 'no pain' (score 0 mm) and 'extreme pain' (score 100 mm). (2) The Western Ontario and McMaster Universities (WOMAC) OA index (24 items, total score=96) (Likert V.3.1) and its pain subscale (7 items, total score=28) and physical function subscale (17 items, total score=68). This is a disease-specific self-report instrument that has been ▸ Standing hip abduction with thera-band elastic resistance band ▸ Place looped thera-band elastic resistance band around both legs just above the ankle ▸ Adequate tension on the elastic band and correct upright posture, with shoulders and hips both facing forward, is required prior to starting the exercise ▸ The back of a chair or a wall can be used to provide support ▸ Hold for 5 s and then lower slowly 
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shown to be valid, reliable and responsive in an extensive range of studies of people with OA. (3) Global perceived effect of treatment, where each participant's perceived response to therapy is assessed using a sevenpoint Likert scale ranging from 'completely recovered' to 'vastly worsened'. This outcome will only be used in the follow-up assessment.
Measures of pain mechanisms
Measures of pain mechanisms will be performed in the same order for all participants.
I. Pressure pain thresholds (PPT): PPT will be measured using a hand-held pressure algometer (FORCE TEN FDX compact digital force gauge, Wagner Instruments, USA). The probe (size 1 cm 2 ) will be applied perpendicular to the skin (rate 40 kPa/s) until the participant first reports that the sensation of pressure has changed to pain. PPTs will be measured three times at each of the following sites: (1) ipsilateral tibialis anterior (10 cm distal to the tibial tuberosity) and (2) ipsilateral extensor carpi radialis longus (10 cm distal to the lateral epicondyle of the humerus) and eight sites in the peripatellar region: Steps (A).
Step ups: ▸ Place symptomatic leg onto the step ▸ Slowly step up onto the step ▸ Touch foot of non-affected leg onto the step then place both feet back onto the starting position on the ground First increase the height of the step and second, add weight Weight can be held across the chest with both hands or use two hand weights 3 sets of 10 30-60 s break period in between sets (B).
Step downs: ▸ Start with both legs standing on top of the step ▸ Bend the knee of the affected leg slowly to lower the non-affected leg towards the ground ▸ Then straighten the affected knee slowly to return to the starting position ▸ The knee of the affected leg must point forward during the movement (1) 2 cm distal to the inferior medial edge of patella; (2) 2 cm distal to the interior lateral edge of patella; (3) 3 cm lateral to the midpoint of the lateral patellar border; (4) 2 cm proximal to the superior lateral edge of patella; (5) 2 cm proximal to the midpoint of the superior patellar border; (6) 2 cm proximal to the superior medial edge of patellar; (7) 3 cm medial to the midpoint of the medial patellar border and (8) centre of the patella. 35 The average of the three measurements at each site will be used in the analysis. PPT measures have been shown to be reliable in knee OA (intraclass correlation coefficient (ICC) =0.83 (0.72-0.90)). 36 II. Heat pain thresholds (HPT): HPT will be measured using the conditioned pain modulation system (Thermal Sensory Analyser, TSA-2001, Q-Sense-CPM, Medoc Ltd, Ramat Yishai, Israel). A 30×30 mm Peltier-based thermode will be placed on the skin. The temperature will start at 32°C and increase at a rate of 0.5°C/s. Participants will push a button when the sensation of heat first turns to a sensation of pain. HPTs will be measured around the peripatellar region (3 sites: medial, patella and lateral knee joint lines) and at the bilateral ventral aspect of the forearm (10 cm distal from the elbow crest). Three measurements will be recorded at each site and the average at each side will be analysed. HPT measure have been shown to have moderate reliability in knee OA (ICC=0.77 (0.62-0.87)).
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III. Conditioned pain modulation (CPM): CPM is a wellestablished, reliable and safe measure of pain processing that is thought to indicate the function of descending pain control systems. This is examined as a change in the pain perceived in one body region (test stimulation) as a result of pain induced in another body region (conditioned stimulation). We will use PPT measurement as the test stimulation and heat pain (1°C above HPT) as the conditioned stimulation using the CPM System (Thermal Sensory Analyser, TSA-2001, Q-Sense-CPM, Medoc Ltd). Three PPTs (test stimulation) will be measured before the application of heat pain (conditioned stimulation). The heat pain will then be applied via a 30×30 mm thermode. Three PPT measurements will be repeated 30 s after applying the conditioned stimulation. Participants will be asked to rate their pain during conditioned stimulation on a numeric rating scale (0-100) at 0 s, 30 s and at the end of the trial. Pain scores will be maintained between 50/100 and 80/100 during testing. Participants will complete two trials in random order: (1) test stimulation at knee and conditioned stimulation at the contralateral forearm and (2) test stimulation at the contralateral forearm and conditioned stimulation at the ipsilateral forearm. The CPM paradigm has shown good intrasession reliability (ICC>0.75).
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IV. Nociceptive flexor withdrawal reflex (NFR): NFR is a measure of central sensitisation and descending pain control systems, and was used in previous studies investigating central sensitisation in knee OA. 38 Surface stimulating electrodes will be positioned at a retromalleolar location along the sural nerve on the side of the painful knee. Recording electrodes will be positioned over the belly of the biceps femoris muscle. Stimulation will consist of five rectangular pulses of 1 ms duration with a 3 ms interval, and will proceed using an up and down staircase method. The intensity needed to evoke a response from the biceps femoris (indicating activation of the NFR), the area of the NFR response and the subjective pain threshold will be recorded. The NFR is a reliable experimental test (intersession coefficient of variation (CV SEM )=16.9%, ICC=0.82). 39 Sample size and analysis This is a pilot study designed to generate data that can be used to inform a future large randomised controlled trial should the intervention appear feasible, safe and show trends of effectiveness. Thus, we have selected a sample size of 10 individuals per group, or a total of 20 participants. A sample size of 20 participants was selected as this is considered achievable within the time frame allocated for completion of the pilot study according to study recruitment rates within the laboratory. We aim to evaluate key trial parameters, such as recruitment and retention of participants, randomisation, levels of missing data and preliminary indications of effectiveness, to inform calculation of a sample size for powering a full trial. As this was a pilot study, a prospective sample size calculation was not conducted.
Data for feasibility and safety will be analysed using descriptive statistics. The percentage of participants who (1) meet the inclusion criteria, (2) agree to be randomised, (3) complete the intervention and (4) attend the follow-up assessment will be calculated. Feasibility will be measured as (1) the number of sessions attended by each participant, (2) number of drop-outs in each group, (3) proportion of participants recruited from the total number screened, (4) willingness of each participant to undergo therapy on an 11-point numerical rating scale with 'not at all willing' at 0 and 'very willing' at 10 (measured at baseline) and (5) the number of home exercise sessions completed. Safety will be presented as any adverse reaction reported on verbal questioning by the treating physiotherapist at each session. An adverse reaction is defined by WHO as "a response to a drug [intervention] which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function" and that likely has a causal relationship with the intervention. 40 A mild tingling or itching sensation under the electrodes, fatigue, headache, nausea and insomnia have been reported as potential adverse reactions following tDCS. 41 Potential adverse reactions as a result of the physical component of the intervention (muscle strengthening exercise) may include increased pain or muscle soreness around the knee joint and thigh. As potential adverse reactions are distinct for each component of the intervention, and as this trial includes a control group receiving sham tDCS, while both groups receive exercise, it should be possible to attribute any reported adverse reactions to either tDCS or exercise. The treating physiotherapist will record a description of any adverse reactions along with the severity, duration and how the adverse reaction was managed. The number of participants reporting adverse reactions, and the duration and severity of the adverse reactions will be reported.
To determine trends of effectiveness, analyses of pain, disability and pain system function will be performed according to intention-to-treat and per protocol using analysis of variance (ANOVA) to assess the changes within groups and the differences between groups over time (pre/post). Repeated measures of ANOVA will be used with factors of intervention (active tDCS/sham tDCS) and time (pre-intervention/post-intervention) as separate twolevel factors. Effect size will be determined using partial η 2 from planned contrasts. The size of the treatment effects will be used to determine whether it is worthwhile to conduct a full randomised controlled trial in the future. 42 43 Given the pilot nature of this trial, missing data will not be replaced. Bonferroni post hoc tests will be applied if appropriate. The α will be set at 0.05.
Means and standard deviations (SDs) for measures of pain, function and pain mechanisms will be used to perform a sample size estimate. Power will be set at 80% to detect between-group differences, with an α of 0.05 and a drop-out rate based on that of the pilot trial. SigmaPlot will be used to analyse the data in this trial.
DISSEMINATION
All participants will provide written informed consent following verbal and written explanation of the study protocol and the opportunity to ask questions. Participants are free to withdraw from the trial at any time without prejudice to future treatment. Results will be presented at scientific meetings and published in peer-reviewed journals. All publications and presentations related to the study will be authorised and reviewed by the study investigators.
TRIAL STATUS
This trial is currently recruiting and is expected to be completed (including follow-up testing) by August 2015.
